Melasma and its impact on health-related quality of life in Hispanic women

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 5-9

  Pawaskar, Manjiri D ^a   Parikh, Parth ^a   Markowski, Tania ^b   Mcmichael, Amy J ^b   Feldman, Steven R ^b   Balkrishnan, Rajesh ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Hispanic American; Hyperpigmentation; Instrumentation; Melanosis; Melasma; Quality of life; Women's health

Indexed keywords

FLUOCINOLONE ACETONIDE; HYDROQUININE; RETINOIC ACID;

CHLOASMA; EMOTION; HEALTH; HISPANIC; HUMAN; MEDICAL LITERATURE; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL LIFE; SOCIAL PSYCHOLOGY;

FEMALE; HEALTH STATUS; HISPANIC AMERICANS; HUMANS; INTERPERSONAL RELATIONS; LEISURE ACTIVITIES; MELANOSIS; QUALITY OF LIFE; QUESTIONNAIRES; UNITED STATES;

EID: 33947150419     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028778     Document Type: Review

References (22)

1. Grimes PE. Melasma: Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-7.
2. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91-8.
3. Grimes P. Incidence and psychosocial implications of melasma. Poster presented at the American Academy of Dermatology, Summer Meeting, New York, New York, 2003.
4. Irwin M. Freedberg, Arthur Z. Eisen, Klauss Wolff, K. Frank Austen, Lowell A. Goldsmith, Stephen Katz. Disorders of pigmentation. In: Fitzgerald TB, editor. Dermatology in general medicine. 4th ed. New York: McGraw Hill, 1999.
5. Arenas R. Melasma. In: Arenas R, editor. Dermatologia: Atlas, diagnostico y tratamiento. Mexico City, Mexico: Interamericana-McGraw-Hill, 1996. p. 96.
6. Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin. 2003;21:601-7.
7. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-7.
8. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37:41-50.
9. Finlay AY. Quality of life measurement in dermatology: A practical guide. Br J Dermatol. 1997;136:305-14.
10. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105-10.
11. Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR, et al. Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation. Health Psychol. 1998;17:530-6.
12. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610-16.
13. Balkrishnan R, Feldman SR, McMichael AJ, DeHart KE, Cayce K, Fleischer AB Jr. Racial differences in the treatment of pigmentation disorders in outpatient settings: Analysis of US national practice data. J Dermatolog Treat. 2004;15:227-30.
14. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004;3(5 suppl):S27-34.
15. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ, et al. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707-13.
16. Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: Cross-cultural adaptation and validation of quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006;55:59-66.
17. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006;54(5 suppl 2):S272-81.
18. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.
19. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: A safe and efficacious 12-month treatment for melasma. Cutis. 2005;75:57-62.
20. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: The pigment trial. J Drugs Dermatol. 2004;3:377-81.
21. Stulberg DL, Clark N. Common hyperpigmentation disorders in adults: Part II. Melanoma, seborrheic keratoses. Acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am Fam Physician. 2003;68:1963-8.
22. Rendon MI. Utilizing combination therapy to optimize melasma outcomes. J Drugs Dermatol. 2004 Sep-Oct;3(5 Suppl):S27-34.